Plain-English translation of NCT02354014 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called bedaquiline can help treat a serious form of tuberculosis that no longer responds to standard antibiotics. The study includes children and teens from birth to age 17 and will look at how safe the medication is, how well the body processes it, and whether it actually works to fight the TB infection. Each child's dose is carefully adjusted based on their age and weight.
Some children develop tuberculosis that doesn't respond to the most common TB drugs, making treatment much harder and more dangerous. This medication offers a promising new option, but doctors need to learn the safest and most effective way to use it in young patients, since children's bodies handle medicines differently than adults.
You would take the new medication by mouth, starting with higher daily doses for the first two weeks, then switching to lower doses three times per week for the next 22 weeks—all while continuing your other TB medicines. The doses are customized for your age group (babies, toddlers, younger children, or teens each receive different amounts). Throughout the study, you'll have regular visits to check that the medication is working, measure how much of it is in your blood, and watch for any side effects.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
Mozambique
Philippines
Russia